Rigel Pharmaceuticals, Inc. (RIGL) NASDAQ

Currency In USD

Key Executives

Name	Title	Pay	Year Born
Raul R. Rodriguez	President, Chief Executive Officer & Director	1.47M	1961
Raymond J. Furey	Executive Vice President, Chief Compliance Officer, General Counsel & Corporate Secretary	803,223	1968
Dean L. Schorno	Executive Vice President & Chief Financial Officer	856,130	1963
Lisa Rojkjaer	Executive Vice President & Chief Medical Officer	863,896	1966
David A. Santos	Executive Vice President & Chief Commercial Officer	865,325	1963
Joseph Lasaga	Executive Vice President & Chief Business Officer	0	1975
Tarek Sallam	Vice President of Marketing	0	N/A
Julie Patel	Senior Vice President of Human Resources	0	N/A

Name

Title

Pay

Year Born

Raul R. Rodriguez

President, Chief Executive Officer & Director

1.47M

1961

Raymond J. Furey

Executive Vice President, Chief Compliance Officer, General Counsel & Corporate Secretary

803,223

1968

Dean L. Schorno

Executive Vice President & Chief Financial Officer

856,130

1963

Lisa Rojkjaer

Executive Vice President & Chief Medical Officer

863,896

1966

David A. Santos

Executive Vice President & Chief Commercial Officer

865,325

1963

Joseph Lasaga

Executive Vice President & Chief Business Officer

1975

Tarek Sallam

Vice President of Marketing

N/A

Julie Patel

Senior Vice President of Human Resources

N/A

Description

Rigel Pharmaceuticals, Inc. is a biotechnology company dedicated to discovering and developing small molecule therapies. The firm's focus areas include hematologic disorders, oncology, and rare immune system conditions. Its commercialized product, Tavalisse (fostamatinib), is an oral spleen tyrosine kinase inhibitor approved for the treatment of chronic immune thrombocytopenia in adult patients. Rigel's robust pipeline features Fostamatinib, currently in Phase III clinical trials for several additional indications, including warm autoimmune hemolytic anemia, as well as separate studies for hospitalized COVID-19 patients and other COVID-19 applications. In its earlier development stages, the company is advancing R289, an oral interleukin receptor associated kinase 1/4 inhibitor undergoing Phase I clinical trials for autoimmune, inflammatory, and hematology-oncology diseases. Another promising compound, R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor, has successfully completed Phase I clinical evaluation for autoimmune and inflammatory conditions. Rigel maintains several strategic collaborations to further its development efforts. These include research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; a partnership with BerGenBio AS focusing on AXL inhibitors in oncology; and an agreement with Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies. The company also has a licensing and supply agreement with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of Fostamatinib. Furthermore, Rigel has a significant collaboration and license agreement with Eli Lilly and Company to jointly develop and commercialize R552 for diverse therapeutic applications, including autoimmune and inflammatory disorders, alongside other non-central nervous system conditions. Founded in 1996, Rigel Pharmaceuticals, Inc. is headquartered in South San Francisco, California.